Novartis AG Logo

Novartis AG

NOVN | SW

Overview

Corporate Details

ISIN(s):
CH0012005267 (+10 more)
LEI:
5493007HIVTX6SY6XD66
Country:
Switzerland
Address:
LICHTSTR. 35, 4056 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novartis AG is a global medicines company that researches, develops, manufactures, and markets innovative pharmaceuticals and healthcare products. The company leverages science and digital technologies to create transformative treatments in areas of high medical need, aiming to improve and extend people's lives. Its portfolio primarily consists of innovative patented medicines and generic pharmaceuticals. Formed in 1997 through a merger of Ciba-Geigy and Sandoz, Novartis is one of the largest pharmaceutical companies worldwide, focused on addressing the evolving needs of patients and healthcare systems.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Novartis AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
Slovene 2.2 MB
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
Slovene 4.4 MB
2023-08-07 08:30
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža
Slovene 2.4 KB
2019-10-22 08:00
Earnings Release
Novartis delivered another strong quarter with double digit sales growth and co…
English 138.9 KB
2019-10-08 08:15
Regulatory News Service
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
English 28.9 KB
2019-10-02 08:15
Regulatory News Service
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
English 21.0 KB
2019-09-29 17:30
Earnings Release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
English 25.3 KB
2019-09-17 08:15
Legal Proceedings Report
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
English 24.4 KB
2019-08-30 08:15
Regulatory News Service
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
English 24.4 KB
2019-07-29 08:00
Regulatory News Service
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
English 29.7 KB
2019-07-18 08:00
Earnings Release
Novartis delivers strong sales, double digit core operating income growth and l…
English 137.7 KB
2019-07-01 18:30
M&A Activity
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
English 19.0 KB
2019-06-07 08:00
Board/Management Information
Novartis announces new leader of Pharmaceuticals Business Unit
English 18.1 KB
2019-04-24 08:00
Earnings Release
Novartis starts 2019 with strong sales and double digit core1 operating income …
English 95.6 KB
2019-03-27 00:35
Regulatory News Service
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
English 27.7 KB

Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novartis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-30 N/A Executive member Sell None 1,973,993.83 CHF
2025-03-07 N/A Non-Executive member Buy None 160,000.00 CHF
2025-02-11 N/A Executive member Sell None 312,203.18 CHF
2025-02-07 N/A Executive member Sell None 2,500,278.74 CHF
2025-02-05 N/A Executive member Sell None 1,365,687.19 CHF
2025-02-04 N/A Executive member Sell None 1,840,201.00 CHF
2025-01-30 N/A Executive member Buy None 699,424.74 CHF
2025-01-30 N/A Executive member Buy None 698,883.18 CHF
2024-12-19 N/A Executive member Sell None 1.00 CHF
2024-11-29 N/A Executive member Sell None 167,294.98 CHF

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK